Download
s00406-021-01287-3.pdf 668,20KB
WeightNameValue
1000 Titel
  • Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs
1000 Autor/in
  1. Hebel, Tobias |
  2. Abdelnaim, M. A. |
  3. Deppe, M. |
  4. Kreuzer, P. M. |
  5. Mohonko, A. |
  6. Poeppl, T. B. |
  7. Rupprecht, R. |
  8. Langguth, B. |
  9. Schecklmann, M. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-03
1000 Erschienen in
1000 Quellenangabe
  • 271(7):1245-1253
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00406-021-01287-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429361/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Introduction!#!The effect of concomitant medication on repetitive transcranial magnetic stimulation (rTMS) outcomes in depression remains understudied. Recent analyses show attenuation of rTMS effects by antipsychotic medication and benzodiazepines, but data on the effects of antiepileptic drugs and lithium used as mood stabilizers or augmenting agents are sparse despite clinical relevance. Preclinical electrophysiological studies suggest relevant impact of the medication on treatment, but this might not translate into clinical practice. We aimed to investigate the role of lithium (Li), lamotrigine (LTG) and valproic acid (VPA) by analyzing rTMS treatment outcomes in depressed patients.!##!Methods!#!299 patients with uni- and bipolar depression treated with rTMS were selected for analysis in respect to intake of lithium, lamotrigine and valproic acid. The majority (n = 251) were treated with high-frequency (10-20 Hz) rTMS of the lDLPFC for an average of 17 treatment sessions with a figure-of-8 coil with a MagVenture system aiming for 110% resting motor threshold, and smaller groups of patients were being treated with other protocols including intermittent theta-burst stimulation and bilateral prefrontal and medial prefrontal protocols. For group comparisons, we used analysis of variance with the between-subjects factor group or Chi-Square Test of Independence depending on the scales of measurement. For post-hoc tests, we used least significant difference (LSD). For differences in treatment effects between groups, we used an ANOVA with the between-subjects factor group (groups: no mood stabilizer, Li, LTG, VPA, Li + LTG) the within-subjects factor treatment (pre vs. post treatment with rTMS) and also Chi-Square Tests of independence for response and remission.!##!Results!#!Overall, patients showed an amelioration of symptoms with no significant differences for the main effect of group and for the interaction effect treatment by group. Based on direct comparisons between the single groups taking mood stabilizers against the group taking no mood stabilizers, we see a superior effect of lamotrigine, valproic acid and combination of lithium and lamotrigine for the response and remission rates. Motor threshold was significantly and markedly higher for patients taking valproic acid.!##!Conclusion!#!Being treated with lithium, lamotrigine and valproic acid had no relevant influence on rTMS treatment outcome. The results suggest there is no reason for clinicians to withhold or withdraw these types of medication from patients who are about to undergo a course of rTMS. Prospective controlled work on the subject is encouraged.
1000 Sacherschließung
lokal Lithium
lokal Transcranial Magnetic Stimulation [MeSH]
lokal Antipsychotic Agents/therapeutic use [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal rTMS
lokal Valproic Acid/therapeutic use [MeSH]
lokal Valproic acid
lokal Anticonvulsants/therapeutic use [MeSH]
lokal Depression
lokal Lamotrigine/therapeutic use [MeSH]
lokal Depression/therapy [MeSH]
lokal Original Paper
lokal Repetitive transcranial magnetic stimulation
lokal Lamotrigine
lokal Antidepressive Agents/therapeutic use [MeSH]
lokal Depression/drug therapy [MeSH]
lokal Mood stabilizer
lokal Lithium/therapeutic use [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-9586-3340|https://frl.publisso.de/adhoc/uri/QWJkZWxuYWltLCBNLiBBLg==|https://frl.publisso.de/adhoc/uri/RGVwcGUsIE0u|https://frl.publisso.de/adhoc/uri/S3JldXplciwgUC4gTS4=|https://frl.publisso.de/adhoc/uri/TW9ob25rbywgQS4=|https://frl.publisso.de/adhoc/uri/UG9lcHBsLCBULiBCLg==|https://frl.publisso.de/adhoc/uri/UnVwcHJlY2h0LCBSLg==|https://frl.publisso.de/adhoc/uri/TGFuZ2d1dGgsIEIu|https://frl.publisso.de/adhoc/uri/U2NoZWNrbG1hbm4sIE0u
1000 Hinweis
  • DeepGreen-ID: 6e8fd20cbc7346a18953f80b23471e14 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6447272.rdf
1000 Erstellt am 2023-04-28T15:35:08.193+0200
1000 Erstellt von 322
1000 beschreibt frl:6447272
1000 Zuletzt bearbeitet Fri Oct 20 20:21:55 CEST 2023
1000 Objekt bearb. Fri Oct 20 20:21:55 CEST 2023
1000 Vgl. frl:6447272
1000 Oai Id
  1. oai:frl.publisso.de:frl:6447272 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source